[Development of a new approach to the pathogenetic therapy of oncological patients].
Basing on the current data and results of the author's own clinical and experimental studies the possibility to intensify the antitumoural resistivity of the organism was established. This may be performed due to demasking of tumour cells using fibrinolytic agents, selective inhibition of tumour cell division by keilons, tissue-specific inhibitors, and also by normalization of the interferon system function.
L N
LN
Mkrtchian
S G
SG
Shukurian
L A
LA
Kamalian
K A
KA
Aleksanian
A M
AM
Ambartsumian
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use; D007372:Interferons / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D005343:Fibrinolytic Agents; D006131:Growth Inhibitors; D007369:Interferon Inducers; D007372:Interferons
Razrabotka kompleksnogo podkhoda k patogeneticheskoĭ terapii onkologicheskikh bol'nykh.